Alastair C McGregor
Overview
Explore the profile of Alastair C McGregor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
954
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu X, Munro A, Wright A, Feng S, Janani L, Aley P, et al.
J Infect
. 2023 Apr;
87(1):18-26.
PMID: 37085049
Background: COV-BOOST is a multicentre, randomised, controlled, phase 2 trial of seven COVID-19 vaccines used as a third booster dose in June 2021. Monovalent messenger RNA (mRNA) COVID-19 vaccines were...
2.
Liu X, Munro A, Feng S, Janani L, Aley P, Babbage G, et al.
J Infect
. 2023 Apr;
86(5):540-541.
PMID: 37055303
No abstract available.
3.
Munro A, Feng S, Janani L, Cornelius V, Aley P, Babbage G, et al.
Lancet Infect Dis
. 2022 May;
22(8):1131-1141.
PMID: 35550261
Background: Some high-income countries have deployed fourth doses of COVID-19 vaccines, but the clinical need, effectiveness, timing, and dose of a fourth dose remain uncertain. We aimed to investigate the...
4.
Liu X, Munro A, Feng S, Janani L, Aley P, Babbage G, et al.
J Infect
. 2022 Apr;
84(6):795-813.
PMID: 35405168
Objectives: To evaluate the persistence of immunogenicity three months after third dose boosters. Methods: COV-BOOST is a multicentre, randomised, controlled, phase 2 trial of seven COVID-19 vaccines used as a...
5.
Munro A, Janani L, Cornelius V, Aley P, Babbage G, Baxter D, et al.
Lancet
. 2021 Dec;
398(10318):2258-2276.
PMID: 34863358
Background: Few data exist on the comparative safety and immunogenicity of different COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection of booster vaccines, we...
6.
Emary K, Golubchik T, Aley P, Ariani C, Angus B, Bibi S, et al.
Lancet
. 2021 Apr;
397(10282):1351-1362.
PMID: 33798499
Background: A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy of...
7.
Ming D, Armstrong M, Lowe P, Chiodini P, Doherty J, Whitty C, et al.
Am J Trop Med Hyg
. 2019 Jun;
101(2):428-431.
PMID: 31219002
This study describes the clinical features of a cohort of imported cases of strongyloidiasis and the performance of standard diagnostic techniques for this condition. A total of 413 cases were...
8.
Neill L, Edwards F, Collin S, Harrington D, Wakerley D, Gopal Rao G, et al.
BMC Infect Dis
. 2019 Jun;
19(1):490.
PMID: 31159769
Background: We describe the clinical features of a cohort of patients with liver abscesses and investigate relationships between clinical, radiological and microbiological findings and mortality. Methods: Retrospective review of pyogenic...
9.
McGregor A, Moore D
Clin Med (Lond)
. 2015 Jun;
15(3):285-7.
PMID: 26031981
The causes of fever of unknown origin (FUO) are changing because advances in clinical practice and diagnostics have facilitated the identification of some infections. A variety of bacterial infections can...
10.
McGregor A, Wright S
Clin Med (Lond)
. 2015 Feb;
15(1):93-5.
PMID: 25650209
Diarrhoea is probably the single most common medical complaint in returning travellers. The most common pathogens are entero-toxigenic Escherichia coli, Shigella, Salmonella and Campylobacter. Viruses, toxigenic Arcobacter and Bacteroides fragilis,...